- Nutex Health reported third quarter 2026 revenue of US$217.61 million and net income of US$40.23 million, with basic EPS from continuing operations of US$5.87, alongside nine month revenue of US$644.85 million and net income of US$152.88 million.
- The nine month net income of US$152.88 million compared with US$58.96 million a year earlier signals a materially different earnings mix than the softer third quarter snapshot alone might suggest.
- We will look at how Nutex Health's mixed quarter and stronger nine month net income shape the broader investment narrative.
Nutex Health Investment Narrative Recap
To stay invested in Nutex Health, you need to be comfortable with a business that leans heavily on the No Surprises Act arbitration process while pushing growth in micro hospitals and Population Health. The latest quarter showed softer revenue and earnings against last year, yet the nine month figures highlight that profit remains supported by factors such as arbitration collections and operating leverage.
The short term swing factor is whether reimbursement pressure on physician fees and revenue per visit stabilises, since the analyst consensus Narrative on Simply Wall St still leans on hospital division economics and visit growth. The key risk is that one off IDR catch up benefits and favourable collection revisions fade further, which could keep reported revenue and margins under strain even if volumes look healthy.
The most relevant context for this earnings release is Nutex Health’s emphasis on micro hospital expansion and Population Health growth in the analyst consensus Narrative on Simply Wall St. Management has talked about opening 3 to 5 facilities per year and building Florida hospital real estate internally with planned sale leasebacks, which is intended to support capacity and funding over time.
These plans matter because the third quarter numbers show how dependent reported performance can be on arbitration items and prior year clean ups. As new hospitals ramp and Population Health adds IPAs and covered lives, you are effectively judging whether more stable membership revenue and lower arbitration contract costs can offset any further pressure from IDR rule changes or weaker professional collections.
Nutex Health’s current earnings are about US$164.7 million, and analyst forecasts imply revenue growth of 11.0% per year, with profit expected to reach US$207.7 million by 2029. This represents roughly a US$43 million increase in earnings and corresponds to projected 2029 revenues of US$1.1b.
Uncover why Nutex Health's fair value indicates a 57% potential upside to its current price, which could narrow quickly.
Exploring Other Perspectives
For Nutex Health, the most cautious analysts focus on execution risk around new micro hospitals. Before this earnings release, that group was working off forecasts that only reach about US$1.1b of revenue and US$195.0 million of earnings by 2029. That is a tighter and more pessimistic story than consensus, so treat today’s results as a prompt to compare several viewpoints before deciding what makes sense to you.
Explore 6 other Nutex Health fair value estimates, including one that suggests there could be as much as 82% downside from the current price.
Reach Your Own Conclusion
Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.
- A great starting point for your Nutex Health research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.
- See our latest analysis for Nutex Health. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Nutex Health's overall financial health at a glance.
Looking for more investment ideas beyond Nutex Health?
Once you have a view on Nutex Health, it can help to line it up against other businesses with different risk and income profiles using the Simply Wall St Screener.
- If capital preservation matters most to you, start with a group of businesses that screen for resilience and lower risk by reviewing the 30 resilient stocks with low risk scores.
- If value is your priority, compare Nutex Health with companies that pair strong fundamentals and attractive pricing by checking the 32 high quality undervalued stocks.
- If income is a key part of your plan, round out your watchlist with higher yielding opportunities through the 6 dividend fortresses.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com